vs
Side-by-side financial comparison of Pacira BioSciences, Inc. (PCRX) and Palomar Holdings, Inc. (PLMR). Click either name above to swap in a different company.
Palomar Holdings, Inc. is the larger business by last-quarter revenue ($253.4M vs $177.4M, roughly 1.4× Pacira BioSciences, Inc.). On growth, Palomar Holdings, Inc. posted the faster year-over-year revenue change (62.7% vs 5.0%). Over the past eight quarters, Palomar Holdings, Inc.'s revenue compounded faster (46.2% CAGR vs -0.2%).
Pacira BioSciences, Inc. is a specialty pharmaceutical company focused on developing and commercializing non-opioid pain management solutions. Its core product line targets post-surgical pain relief for patients, serving hospitals, ambulatory surgery centers and other healthcare providers primarily in the U.S., with ongoing expansion efforts in select international markets.
Palomar Holdings, Inc. is a specialty insurance holding company that primarily provides property insurance products for catastrophe-exposed residential and commercial assets. It mainly operates across the United States, focusing on core segments including earthquake, flood, and windstorm coverage to meet high-risk property protection demands of customers.
PCRX vs PLMR — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $177.4M | $253.4M |
| Net Profit | $2.9M | — |
| Gross Margin | — | — |
| Operating Margin | 3.9% | 28.7% |
| Net Margin | 1.6% | — |
| Revenue YoY | 5.0% | 62.7% |
| Net Profit YoY | — | — |
| EPS (diluted) | $0.07 | $2.05 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $177.4M | — | ||
| Q4 25 | $196.9M | $253.4M | ||
| Q3 25 | $179.5M | $244.7M | ||
| Q2 25 | $181.1M | $203.3M | ||
| Q1 25 | $168.9M | $174.6M | ||
| Q4 24 | $187.3M | $155.8M | ||
| Q3 24 | $168.6M | $148.5M | ||
| Q2 24 | $178.0M | $131.1M |
| Q1 26 | $2.9M | — | ||
| Q4 25 | — | — | ||
| Q3 25 | $5.4M | $51.5M | ||
| Q2 25 | $-4.8M | $46.5M | ||
| Q1 25 | $4.8M | $42.9M | ||
| Q4 24 | — | — | ||
| Q3 24 | $-143.5M | $30.5M | ||
| Q2 24 | $18.9M | $25.7M |
| Q1 26 | — | — | ||
| Q4 25 | 79.5% | — | ||
| Q3 25 | 80.9% | — | ||
| Q2 25 | 77.4% | — | ||
| Q1 25 | 79.7% | — | ||
| Q4 24 | 78.7% | — | ||
| Q3 24 | 76.9% | — | ||
| Q2 24 | 75.1% | — |
| Q1 26 | 3.9% | — | ||
| Q4 25 | 1.2% | 28.7% | ||
| Q3 25 | 3.5% | 27.4% | ||
| Q2 25 | 4.7% | 29.5% | ||
| Q1 25 | 1.2% | 30.8% | ||
| Q4 24 | 13.2% | 28.9% | ||
| Q3 24 | -82.8% | 25.9% | ||
| Q2 24 | 15.9% | 25.5% |
| Q1 26 | 1.6% | — | ||
| Q4 25 | — | — | ||
| Q3 25 | 3.0% | 21.0% | ||
| Q2 25 | -2.7% | 22.9% | ||
| Q1 25 | 2.8% | 24.6% | ||
| Q4 24 | — | — | ||
| Q3 24 | -85.1% | 20.5% | ||
| Q2 24 | 10.6% | 19.6% |
| Q1 26 | $0.07 | — | ||
| Q4 25 | $0.05 | $2.05 | ||
| Q3 25 | $0.12 | $1.87 | ||
| Q2 25 | $-0.11 | $1.68 | ||
| Q1 25 | $0.10 | $1.57 | ||
| Q4 24 | $0.38 | $1.29 | ||
| Q3 24 | $-3.11 | $1.15 | ||
| Q2 24 | $0.39 | $1.00 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $144.3M | $106.9M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $653.9M | $942.7M |
| Total Assets | $1.2B | $3.1B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $144.3M | — | ||
| Q4 25 | $238.4M | $106.9M | ||
| Q3 25 | $246.3M | $111.7M | ||
| Q2 25 | $445.9M | $81.3M | ||
| Q1 25 | $493.6M | $119.3M | ||
| Q4 24 | $484.6M | $80.4M | ||
| Q3 24 | $453.8M | $86.5M | ||
| Q2 24 | $404.2M | $47.8M |
| Q1 26 | — | — | ||
| Q4 25 | $372.2M | — | ||
| Q3 25 | $376.7M | — | ||
| Q2 25 | $580.5M | — | ||
| Q1 25 | $583.4M | — | ||
| Q4 24 | $585.3M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | $653.9M | — | ||
| Q4 25 | $693.1M | $942.7M | ||
| Q3 25 | $727.2M | $878.1M | ||
| Q2 25 | $757.8M | $847.2M | ||
| Q1 25 | $798.5M | $790.4M | ||
| Q4 24 | $778.3M | $729.0M | ||
| Q3 24 | $749.6M | $703.3M | ||
| Q2 24 | $879.3M | $532.6M |
| Q1 26 | $1.2B | — | ||
| Q4 25 | $1.3B | $3.1B | ||
| Q3 25 | $1.3B | $2.9B | ||
| Q2 25 | $1.5B | $2.8B | ||
| Q1 25 | $1.6B | $2.4B | ||
| Q4 24 | $1.6B | $2.3B | ||
| Q3 24 | $1.5B | $2.3B | ||
| Q2 24 | $1.6B | $2.0B |
| Q1 26 | — | — | ||
| Q4 25 | 0.54× | — | ||
| Q3 25 | 0.52× | — | ||
| Q2 25 | 0.77× | — | ||
| Q1 25 | 0.73× | — | ||
| Q4 24 | 0.75× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $409.1M |
| Free Cash FlowOCF − Capex | — | $409.0M |
| FCF MarginFCF / Revenue | — | 161.4% |
| Capex IntensityCapex / Revenue | — | 0.1% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $700.6M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $43.7M | $409.1M | ||
| Q3 25 | $60.8M | $83.6M | ||
| Q2 25 | $12.0M | $120.9M | ||
| Q1 25 | $35.5M | $87.2M | ||
| Q4 24 | $33.1M | $261.2M | ||
| Q3 24 | $53.9M | $100.3M | ||
| Q2 24 | $53.2M | $55.1M |
| Q1 26 | — | — | ||
| Q4 25 | $43.5M | $409.0M | ||
| Q3 25 | $57.0M | $83.6M | ||
| Q2 25 | $9.3M | $120.8M | ||
| Q1 25 | $26.9M | $87.1M | ||
| Q4 24 | $31.0M | $260.9M | ||
| Q3 24 | $49.8M | $100.1M | ||
| Q2 24 | $51.6M | — |
| Q1 26 | — | — | ||
| Q4 25 | 22.1% | 161.4% | ||
| Q3 25 | 31.7% | 34.2% | ||
| Q2 25 | 5.1% | 59.4% | ||
| Q1 25 | 15.9% | 49.9% | ||
| Q4 24 | 16.6% | 167.5% | ||
| Q3 24 | 29.6% | 67.4% | ||
| Q2 24 | 29.0% | — |
| Q1 26 | — | — | ||
| Q4 25 | 0.1% | 0.1% | ||
| Q3 25 | 2.2% | 0.0% | ||
| Q2 25 | 1.5% | 0.0% | ||
| Q1 25 | 5.1% | 0.0% | ||
| Q4 24 | 1.1% | 0.2% | ||
| Q3 24 | 2.4% | 0.1% | ||
| Q2 24 | 0.9% | 0.0% |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | 11.20× | 1.63× | ||
| Q2 25 | — | 2.60× | ||
| Q1 25 | 7.37× | 2.03× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 3.29× | ||
| Q2 24 | 2.82× | 2.14× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
PCRX
| EXPAREL | $143.3M | 81% |
| ZILRETTA | $26.8M | 15% |
| iovera° | $6.2M | 3% |
| Bupivacaine liposome injectable suspension | $1.2M | 1% |
PLMR
Segment breakdown not available.
